Gadolinium-based contrast agents, widely used in MRI scans, are generally thought to be safe for patients with normal kidney function. Unfortunately, a new study suggests that trace amounts remain, even in patients with healthy kidneys, and may be linked to brain abnormalities. Medical Imaging Technology asks lead researcher Tomonori Kanda about the significance of his findings and how safety recommendations might be affected.
Gadolinium-based contrast media has long been an area of controversy. Mention the term in radiology circles and discussion will rapidly turn to the association with nephrogenic systemic fibrosis (NSF). This association is now well established; what to do about it remains a question in point.
Unfortunately, NSF is not the only issue making the news. In December 2013, a study in Radiology drew a link between gadolinium-based contrast agents and brain abnormalities, suggesting toxic gadolinium ions may stay in the patient’s brain long after administration. If this idea proves correct, it may be time to re-evaluate current wisdom regarding safety protocols. And, while more research is needed, the study lays down another piece in what is proving to be a complicated puzzle.
The history of gadolinium-based contrast agents is worth recapping. First approved in 1988, gadolinium contrast agents are currently used in around 25–30% of MRI scans every year. There are several varieties but all are administered intravenously and used to heighten contrast between the diseased tissue and its surroundings.
In terms of the risks to patients, gadolinium-based chelates have generally fared well. They are deemed safer, on the whole, than the iodinated contrast media used in CT scans and X-rays, which carry a risk of anaphylaxis and kidney damage. It is estimated that some 200 million doses have been administered in the US, mostly with no discernable ill effects.
In 2006, however, it became apparent that something was amiss. Dr Thomas Grobner, a nephrologist from Austria, noticed a correlation between gadolinium-enhanced MRI and the development of a rare but serious condition: NSF.
First emerging in 1997, NSF is characterised by the fibrosis of skin, joints and internal organs. It can prove extremely debilitating, often leading to wheelchair dependency, and in its worst instances can be fatal. Right from the outset, a certain sufferer profile was apparent: all had chronic kidney disease, and most had received kidney transplants.
Not till Grobner et al, however, did anyone think to draw a link with MR scans. According to his report, five of his patients had developed NSF within weeks of receiving gadolinium contrast injections, and, rather than passing through their bodies as expected, the substance could be identified in their skin tissue. These claims, which caused significant disquiet in the medical community, prompted an FDA investigation.
Since then, evidence has continued to mount, and radiology departments have put firm precautions in place. It is recommended that, for patients with kidney problems, gadolinium-based contrast agents should be used judiciously, if at all. After such guidelines were applied, the incidence of the disease fell from 36.5/100,000 to 4/100,000 patients.
For those with normal renal function, however, the recommendations haven’t changed. Up till now, there has been little to suggest gadolinium might linger in their bodies too.
Link to hyperintensity
The new Radiology paper has a different message. Published online, it involved 35 patients who had undergone brain MR imaging. Nineteen of these subjects had received at least six gadolinium-enhanced examinations and the other 16 had had fewer than six. Following another T1-weighted MRI (this time unenhanced), clear differences in their brains were observed.
The research team, based in Japan, noted a strong correlation between the number of exams and areas of high intensity in their brain. The areas in question were the dentate nucleus (DN) and globus pallidus (GP). Hyperintensity in these regions is associated with multiple sclerosis and hepatic dysfunction respectively, although the exact clinical implications are unclear.
“Abnormal signal intensity in the dentate nucleus and globus pallidus are associated with past gadolinium-based contrast agent exposure,” confirms lead author Tomonori Kanda MD, from Teikyo University School of Medicine in Tokyo and Hyogo Cancer Centre in Akashi. “MRI imaging had not detected this before, but our data suggest the possibility of deposition to the human body.”
This suggestion flies in the face of what is currently believed. In patients with normal renal function, gadolinium elimination is thought to be rapid and complete: toxic gadolinium ions are chemically bonded with non-metal ions (chelation) and quickly removed from the body. According to pharmacokinetic studies, over 90% of the substance is excreted within the first 12 hours.
When a patient has kidney disease, this process is disrupted. Because the substance is eliminated almost exclusively via the kidneys, poor renal function increases the clearance rate and the half-life of the compound in the blood. In the worst-case scenario, it can lead to gadolinium retention within tissues, and, ultimately, NSF.
This is not what is occurring in Kanda’s study. If his work does show toxic gadolinium deposition in the brain, the mechanism would be independent of renal function. Rather, it could be that trace amounts remain, even in patients with healthy kidneys, and gradually start to accrue if the patient receives multiple injections.
No room for complacency
Of course, we have to be careful not to extrapolate too far. This particular study is just a starting point: it didn’t evaluate damage to the human body, and it didn’t assert that gadolinium was responsible for the areas of hyperintensity. And, while it did establish a relationship between multiple injections and brain abnormalities, the nature of this relationship is yet to be determined.
“There are three types of research we should do,” says Kanda. “We need to find out whether the MRI hyperintensity was caused by the gadolinium ion or not; whether the macrocyclic type of contrast agent can prevent MRI hyperintensity or not; and whether the patients who have hyperintensity in their brain had symptoms or not.”
The first of these three speaks for itself. With regard to the second, it should be noted that there are two types of gadolinium-based contrast media – macrocyclic and linear – with distinct chemical configurations. The patients in this study received the linear type only. Macrocyclic agents may prove safer, or at least give different results.
The third angle is the most interesting and the most complex. If we look at the patients who are receiving the multiple injections – that is, the ones who require frequent brain scans – they’re also likely to be the ones who suffer from the most severe diseases. This means that even if gadolinium does accumulate, any symptoms may be obscured and attributed to the disease in question.
It’s also hard to determine whether the areas of brain hyperintensity are due to gadolinium or to the patient’s underlying condition. Untangling what causes what will take a significant amount of research.
With so much yet to be explored, it is safe to assume that FDA recommendations won’t be changing any time soon. But equally, there’s no room for complacency. If gadolinium is not cleared entirely, it may well build up in organs over time. And, while such deposition might prove asymptomatic and ultimately benign, there is also the chance that it might not.
“In 2008, Sieber et al used a mouse model to report that the overdose of gadolinium injections could cause NSF-like lesions even with normal renal function,” says Kanda. “If gadolinium is gradually accumulated, NSF-like lesions may be occurring even in humans.”
For now, he feels radiologists should keep an eye out for developments in this field, as they may be required to implement new rules in future. “If toxic gadolinium accumulation does occur, a limitation in the number of gadolinium injections may be recommended,” he says.
Gadolinium: a timeline
1988 – The first gadolinium-based contrast agent receives approval. GdDTPA (gadopentetate dimeglumine, otherwise known as Magnevist) is an extracellular fluid agent, which works in the spaces between cells. With powerful paramagnetic properties, gadolinium chelates can dramatically heighten the contrast of an image.
1997 – The first case of nephrogenic systemic fibrosis (NSF) is identified.
2000 – NSF is first described in the medical literature. It causes fibrosis of the skin and connective tissues and progressively worsens over time. For now, it is known as nephrogenic fibrosing dermopathy because it manifests primarily in the skin.
2004 – Five gadolinium-based contrast agents (Magnevist, MultiHance, Omniscan, Optimark and ProHance) have now been approved for MRI.
2005 – Sufferers of nephrogenic fibrosing dermopathy have presented with symptoms in the subcutaneous tissue and muscles. The name is changed to NSF.
2006 – 26.9 million MRI scans are performed in the US this year. 45% of them use a gadolinium-based contrast agent.
April 2006 – Grobner et al report in the journal Nephrology Dialysis Transplantation. They suggest NSF may be related to gadolinium-based MRI scans.
December 2006 – The FDA opens investigations into the topic in order to define the risk factors.
2007 – With investigations ongoing, contrast agent manufacturers are required to add a warning to their labels that detail the risk of developing NSF. Incidence of the condition drops.
2010 – Labelling requirements are tightened up. Three contrast agents (Magnevist, Omniscan and Optimark) are described as inappropriate for use among patients with kidney disease, and all labels must emphasise the need to screen patients for kidney dysfunction.
December 2013 – A study by Kanda et al suggests that toxic gadolinium ions may be deposited in the body, even in patients with normal renal function.
This article appears in the 2014 vol. 1 edition of Medical Imaging Technology